SBIR-STTR Award

Monoclonal antibodies directed against cytokines
Profile last edited on: 1/30/14

Program
SBIR
Agency
NIH | NCI
Total Award Amount
$50,000
Award Phase
1
Principal Investigator
Donald S Masters
Activity Indicator

Company Information

Genzyme Corporation (AKA:Biomatrix Inc~genzyme Biosurgery Corporation)

500 Kendall Square
Cambridge, MA 02142
   (617) 252-7500
   information@genzyme.com
   www.genzyme.com
Multiple Locations:   
Congressional District:   07
County:   Middlesex

Phase I

Phase I year
1985
Phase I Amount
$50,000
Heteroantisera against interferon (IFN) and interleukin-2 (IL-2) are highly immunosuppressive when injected into experimental animals. These anticytokines impair the generation of cytolytic T cells, the rejection of transplanted tumors, and other cellular immune functions. Murine monoclonal antibodies against IL-2 have been available for several years, and recently the technology for the generation of human monoclonal antibodies has emerged. Patients treated with IFN in various clinical trials and patients with systemic lupus erythematosis with high endogenous levels of IFN develop antibodies against IFN. Similarly, patients repeatedly injected with recombinant IL-2 as treatment for refractory cancer develop IgG antibodies against IL-2. We propose to generate human hybridomas from the B-lymphocytes of these patients by fusion with human myeloma cell lines. The culture supernatants of these hybridomas will be screened for anti-IL-2 antibodies with a sensitive ELISA and subsequently for the ability to inhibit IL-2-induced T-cell proliferation, cytolytic T-cell induction, and the development of a delayed-type hypersensitivity response to tuberculin. These neutralizing antibodies may be clinically useful in the prevention and treatment of organ allograft rejection and in the treatment of certain T-cell malignancies.National Cancer Institute (NCI)

Phase II

Phase II year
---
Phase II Amount
---